Literature DB >> 21530356

The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications.

Elise Anderson1, John Nutt.   

Abstract

The antiparkinsonian response to levodopa is characterized by an immediate motor improvement lasting hours and a more sustained response lasting days. These two responses have been referred to as the short-duration response (SDR) and the long-duration response (LDR). The LDR represents a substantial component of the clinical effect of levodopa and has been clinically recognized for several decades, but it remains poorly understood. This review will focus on the LDR phenomenology and theories about its origin, with the goal of promoting inquiry into this important but as yet poorly understood aspect of levodopa therapy for PD. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21530356     DOI: 10.1016/j.parkreldis.2011.03.014

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  16 in total

1.  A role for dopamine-mediated learning in the pathophysiology and treatment of Parkinson's disease.

Authors:  Jeff A Beeler; Michael J Frank; John McDaid; Erin Alexander; Susie Turkson; Maria Sol Bernardez Sarria; Maria Sol Bernandez; Daniel S McGehee; Xiaoxi Zhuang
Journal:  Cell Rep       Date:  2012-12-13       Impact factor: 9.423

Review 2.  The missing, the short, and the long: Levodopa responses and dopamine actions.

Authors:  Roger L Albin; Daniel K Leventhal
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

3.  Biphasic (Subtherapeutic) Levodopa-Induced Respiratory Dysfunction in Parkinson Disease.

Authors:  Veerle A van de Wetering-van Dongen; Alberto J Espay; Luca Marsili; Andrea Sturchio; Susanne Ten Holter; Bastiaan R Bloem; Maarten J Nijkrake
Journal:  Neurol Clin Pract       Date:  2021-08

Review 4.  Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Authors:  Maria Eliza Freitas; Christopher W Hess; Susan H Fox
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

5.  Dissociable effects of dopamine on learning and performance within sensorimotor striatum.

Authors:  Daniel K Leventhal; Colin Stoetzner; Rohit Abraham; Jeff Pettibone; Kayla DeMarco; Joshua D Berke
Journal:  Basal Ganglia       Date:  2014-06-01

6.  Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort.

Authors:  Samantha K Holden; Taylor Finseth; Stefan H Sillau; Brian D Berman
Journal:  Mov Disord Clin Pract       Date:  2017-09-22

7.  Optimizing the selection of Parkinson's disease patients for neuromodulation using the levodopa challenge test.

Authors:  Dinkar Kulshreshtha; Marcus Pieterman; Greydon Gilmore; Mandar Jog
Journal:  J Neurol       Date:  2021-06-30       Impact factor: 6.682

8.  Altered Whole-Brain and Network-Based Functional Connectivity in Parkinson's Disease.

Authors:  Laura J de Schipper; Anne Hafkemeijer; Jeroen van der Grond; Johan Marinus; Johanna M L Henselmans; Jacobus J van Hilten
Journal:  Front Neurol       Date:  2018-06-06       Impact factor: 4.003

9.  Objective Measurement and Characterization of Sleep Benefit in Parkinson's Disease.

Authors:  Will Lee; Andrew H Evans; David R Williams
Journal:  Mov Disord Clin Pract       Date:  2017-05-25

Review 10.  The Enemy within: Propagation of Aberrant Corticostriatal Learning to Cortical Function in Parkinson's Disease.

Authors:  Jeff A Beeler; Giselle Petzinger; Michael W Jakowec
Journal:  Front Neurol       Date:  2013-09-12       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.